Tango Therapeutics, Inc.

This study is testing whether a new oral drug called TNG462 is safe and effective when combined with other cancer drugs for people with advanced pancreatic or non-small cell lung cancer. The trial will involve about 183 adults whose cancers have specific genetic changes (MTAP los…

This study is testing a new oral drug called TNG260, given alone and with the immunotherapy pembrolizumab, for people with advanced solid tumors that have a specific genetic change (STK11 mutation). The main goals are to find a safe and effective dose and to see if the treatment …

This study is testing a new oral drug called TNG456, both alone and combined with another cancer drug (abemaciclib), in people with advanced solid tumors that have a specific genetic change called MTAP loss. The main goals are to find safe doses and see if the treatment can shrin…

This early-stage study is testing a new oral medication called TNG462, both alone and combined with an existing immunotherapy drug (pembrolizumab), for people with advanced solid tumors that have a specific genetic change called an MTAP deletion. The main goals are to find safe d…